SERA (Sera Prognostics) Accounts Payable & Accrued Expense : $1.21 Mil (As of Mar. 2025)

View and export this data going back to 2021. Start your Free Trial

What is Sera Prognostics Accounts Payable & Accrued Expense?

Sera Prognostics's quarterly accounts payable & accrued expense increased from Sep. 2024 ($1.86 Mil) to Dec. 2024 ($1.97 Mil) but then declined from Dec. 2024 ($1.97 Mil) to Mar. 2025 ($1.21 Mil).

Sera Prognostics's annual accounts payable & accrued expense declined from Dec. 2022 ($2.55 Mil) to Dec. 2023 ($1.12 Mil) but then increased from Dec. 2023 ($1.12 Mil) to Dec. 2024 ($1.97 Mil).

Sera Prognostics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Sera Prognostics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sera Prognostics Accounts Payable & Accrued Expense Chart

Sera Prognostics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Accounts Payable & Accrued Expense

Get a 7-Day Free Trial

1.73

1.66

2.55

1.12

1.97

Sera Prognostics Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial															1.67	1.63	1.86	1.97	1.21

Sera Prognostics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Sera Prognostics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Sera Prognostics Inc (NAS:SERA) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

2749 East Parleys Way, Suite 200, Salt Lake City, UT, USA, 84109

Website

https://www.seraprognostics.com

Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and services. The Company operates as one operating segment, which is developing and commercializing its medical diagnostic products and services.

Executives

Mansoor Raza Mirza	director	C/O KARYOPHARM THERAPEUTICS INC., 2 MERCER ROAD, NATICK MA 01760
Austin Aerts	officer: Chief Financial Officer	2479 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Robert Gardner Harrison	officer: Chief Information Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Zhenya Lindgardt	director	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 84109
John J. Boniface	officer: Chief Scientific Officer	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Benjamin Jackson	officer: General Counsel	320 WAKARA WAY, SALT LAKE CITY UT 84108
Paul Kearney	officer: Chief Data Officer	2749 E. PARLEYS WAY, C/O SERA PROGNOSTICS, INC., SALT LAKE CITY UT 84109
Joshua Phillips	director	C/O SERA PROGNOSTICS, INC., 2749 EAST PARLEYS WAY, SUITE 200, SALT LAKE CITY UT 84109
Jane F Barlow	director	6800 BROKEN SOUND PARKWAY NW, 3RD FLOOR, BOCA RATON FL 33487
Michael R Foley	officer: Chief Medical Officer	C/O SERA PROGNOSTICS INC, 2749 EAST PARLEYS WAY SUITE 200, SALT LAKE CITY UT 04109
Sandra Aj Lawrence	director	C/O EVERGY, INC., 1200 MAIN STREET, KANSAS CITY MO 64105
Douglas Fisher	officer: Chief Business Officer	587 PATROL RD, WOODSIDE CA 94062
Gregory C Critchfield	director, officer: Chief Executive Officer	320 WAKARA WAY, SALT LAKE CITY UT 84108
Blue Ox Healthcare Partners Sp, Llc	10 percent owner	135 E. 57TH STREET, 23RD FLOOR, NEW YORK NY 10022
Bxhcp Sp Ii, Llc	10 percent owner	135 E 57TH STREET, 23RD FLOOR, NEW YORK NY 10022